India may shortly receive a third vaccine for the novel coronavirus. As more states announce a scarcity of Covid-19 vaccine doses, the Subject Expert Committee (SEC) will meet today to consider the Sputnik V application for emergency use authorization in India, according to the news agency ANI.
COVID19 A Subject Expert Committee will meet today to discuss the Sputnik V application for Emergency Use Authorization in India: References
According to top government reports, India will receive vaccines from five additional manufacturers by the end of the third quarter of this year. Covishield and Covaxin are currently manufactured in India.
“India currently manufactures two COVID-19 vaccines: Covishield and Covaxin, with five more vaccines expected by Q3 2021. Sputnik V vaccine (developed in collaboration with Dr. Reddy’s), Johnson & Johnson vaccine (developed in collaboration with Biological E), Novavax vaccine (developed in collaboration with Serum India), Zydus Cadila’s vaccine, and Bharat Biotech’s Intranasal Vaccine are among these vaccines. The Union government’s primary considerations when giving emergency use authorization (EUA) to every COVID-19 vaccine in the country are safety and effectiveness.” According to ANI, the source.
Sputnik V vaccine will be the first to be approved out of about 20 COVID-19 vaccines in different clinical and pre-clinical phases. Sputnik is scheduled to receive the EUA within the next ten days.
The Russian Direct Investment Fund (RDIF) has partnered with a number of Indian pharmaceutical companies, including Panacea Biotec, Dr. Reddy’s Laboratories, and Gland Pharma, to manufacture vaccine doses. Today, Dr. Reddy’s stock was up 2%.
India is now experiencing the second wave of the COVID-19 pandemic, with new cases being reported on a daily basis. According to Union Health Ministry data updated on Monday, the country set a new coronavirus infection record today, with 1,68,912 new cases, the largest single-day increase so far, bringing the cumulative number of cases to 1,35,27,717.
The number of active cases has reached 12 lakh, while the death rate has risen to 1,70,179, with 904 reported new deaths, the highest since October 18, according to statistics revised at 8 a.m.
